Ann Arbor, MI, USA
Develop, characterize, and validate peptide ligands that bind cancer-specific targets, including 1) heterodimers for multivalent ligand-target interactions, 2) nanocarriers for site-specific delivery, 3) advanced genomic tools to identify response biomarkers, and 4) small animal imaging (fluorescence, photoacoustic, ultrasound) and therapy, and 5) clinical translation. We use genetics, proteomics, transcriptomics, bioinformatics, biochemistry, and molecular analyses, and single cell RNA-seq analysis of human cells, mouse models, and patient specimens, including organoid cultures.
- PhD degree in biochemistry, chemistry, molecular biology, immunology, or related discipline
- Experience with standard molecular biology techniques, cell culture, and small animals
- Ability to work effectively both independently and as a member of a team
1. Chen J, et al. Multiplexed endoscopic imaging of Barrett’s neoplasia using targeted fluorescent heptapeptides in a phase 1 proof-of-concept study. Gut 2021;70:1010-13. PMC8108279.
2. Joshi BP, et al. Wide-field endoscopic imaging of sessile serrated adenomas with fluorescently-labeled peptide probe. Gastroenterology 2017;152:1002-13. PMC5771498.
3. Sturm MB, et al. Targeted endoscopic imaging of Barrett’s neoplasia with specific fluorescent-labeled peptide: first in-human results. Science Translational Medicine 2013;5:184ra61. PMC3859345.